These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23865362)

  • 1. Prognostic implication of BAALC gene expression in adult acute myeloid leukemia.
    Yahya RS; Sofan MA; Abdelmasseih HM; Saudy N; Sharaf-Eldein MA
    Clin Lab; 2013; 59(5-6):621-8. PubMed ID: 23865362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.
    Damiani D; Tiribelli M; Franzoni A; Michelutti A; Fabbro D; Cavallin M; Toffoletti E; Simeone E; Fanin R; Damante G
    Am J Hematol; 2013 Oct; 88(10):848-52. PubMed ID: 23760853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.
    Baldus CD; Tanner SM; Ruppert AS; Whitman SP; Archer KJ; Marcucci G; Caligiuri MA; Carroll AJ; Vardiman JW; Powell BL; Allen SL; Moore JO; Larson RA; Kolitz JE; de la Chapelle A; Bloomfield CD
    Blood; 2003 Sep; 102(5):1613-8. PubMed ID: 12750167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of combined BAALC and MN1 gene expression level in acute myeloid leukemia with normal karyotype.
    Marjanovic I; Karan-Djurasevic T; Kostic T; Virijevic M; Vukovic NS; Pavlovic S; Tosic N
    Int J Lab Hematol; 2021 Jun; 43(3):433-440. PubMed ID: 33242229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications.
    Baldus CD; Thiede C; Soucek S; Bloomfield CD; Thiel E; Ehninger G
    J Clin Oncol; 2006 Feb; 24(5):790-7. PubMed ID: 16418499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Over expression of brain and acute leukemia, cytoplasmic and ETS-related gene is associated with poor outcome in acute myeloid leukemia.
    Hasan SK; Patkar NV; Rajamanickam D; Gokarn A; Lucena-Araujo AR; Tembhare P; Bagal B; Kadam Amare P; Jain H; Gujral S; Sengar M; Subramanian PG; Khattry N
    Hematol Oncol; 2020 Dec; 38(5):808-816. PubMed ID: 32893896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Zhang J; Shi J; Zhang G; Zhang X; Yang X; Yang S; Wang J; Ke X; Fu L
    Ann Hematol; 2018 Aug; 97(8):1391-1397. PubMed ID: 29696374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BAALC and ERG expression in acute myeloid leukemia with normal karyotype: impact on prognosis.
    Eid MA; Attia M; Abdou S; El-Shazly SF; Elahwal L; Farrag W; Mahmoud L
    Int J Lab Hematol; 2010 Apr; 32(2):197-205. PubMed ID: 19555438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
    Díaz-Beyá M; Brunet S; Nomdedéu J; Cordeiro A; Tormo M; Escoda L; Ribera JM; Arnan M; Heras I; Gallardo D; Bargay J; Queipo de Llano MP; Salamero O; Martí JM; Sampol A; Pedro C; Hoyos M; Pratcorona M; Castellano JJ; Nomdedeu M; Risueño RM; Sierra J; Monzó M; Navarro A; Esteve J
    Blood Cancer J; 2015 Oct; 5(10):e352. PubMed ID: 26430723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.
    Langer C; Radmacher MD; Ruppert AS; Whitman SP; Paschka P; Mrózek K; Baldus CD; Vukosavljevic T; Liu CG; Ross ME; Powell BL; de la Chapelle A; Kolitz JE; Larson RA; Marcucci G; Bloomfield CD;
    Blood; 2008 Jun; 111(11):5371-9. PubMed ID: 18378853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML.
    Jentzsch M; Bill M; Grimm J; Brauer D; Backhaus D; Goldmann K; Schulz J; Niederwieser D; Platzbecker U; Schwind S
    Ann Hematol; 2020 Oct; 99(10):2417-2427. PubMed ID: 32862286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of BAALC: clinical significance in Chinese de novo acute myeloid leukemia.
    Zhou JD; Yang L; Zhang YY; Yang J; Wen XM; Guo H; Yao DM; Ma JC; Chen Q; Lin J; Qian J
    Med Oncol; 2015 Jan; 32(1):386. PubMed ID: 25428390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.
    Metzeler KH; Dufour A; Benthaus T; Hummel M; Sauerland MC; Heinecke A; Berdel WE; Büchner T; Wörmann B; Mansmann U; Braess J; Spiekermann K; Hiddemann W; Buske C; Bohlander SK
    J Clin Oncol; 2009 Oct; 27(30):5031-8. PubMed ID: 19752345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia.
    Haferlach C; Kern W; Schindela S; Kohlmann A; Alpermann T; Schnittger S; Haferlach T
    Genes Chromosomes Cancer; 2012 Mar; 51(3):257-65. PubMed ID: 22072540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML.
    Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
    Eur J Haematol; 2013 Aug; 91(2):112-21. PubMed ID: 23672350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low MDR1 and BAALC expression identifies a new subgroup of intermediate cytogenetic risk acute myeloid leukemia with a favorable outcome.
    Guo X; Shi P; Chen F; Zha J; Liu B; Li R; Dong H; Zheng H; Xu B
    Blood Cells Mol Dis; 2014 Sep; 53(3):144-8. PubMed ID: 24855032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implication of higher BAALC expression in combination with other gene mutations in adult cytogenetically normal acute myeloid leukemia.
    Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
    Leuk Lymphoma; 2014 Jan; 55(1):110-20. PubMed ID: 23647058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.
    Eisfeld AK; Marcucci G; Maharry K; Schwind S; Radmacher MD; Nicolet D; Becker H; Mrózek K; Whitman SP; Metzeler KH; Mendler JH; Wu YZ; Liyanarachchi S; Patel R; Baer MR; Powell BL; Carter TH; Moore JO; Kolitz JE; Wetzler M; Caligiuri MA; Larson RA; Tanner SM; de la Chapelle A; Bloomfield CD
    Blood; 2012 Jul; 120(2):249-58. PubMed ID: 22529287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.